Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The proposed Phase 2, single-center, fixed dose, open-label study will explore the efficacy, safety, and tolerability of 25 mg dose of oral psilocybin in conjunction with therapy in cisgender women participants diagnosed with PTSD secondary to an index trauma of sexual assault.